Novo Seeds Provides Business Update on a Record Year – Building Exceptional Companies for Global Impact

  • Over US$ 550 million raised by portfolio companies in 2021
  • IO Biotech IPO on US NASDAQ
  • Forendo Pharma acquired for nearly US$ 1 billion
  • Muna launched with world-leading science to advance latest scientific breakthroughs in neuroscience
  • Adcendo raised US$ 60 million Series A to deliver next-generation Antibody-Drug Conjugates
  • Hemab raised US$ 50 million Series A to develop bispecific antibodies for the treatment of rare bleeding disorders
  • Novo Seeds expanded its bioindustrials portfolio with Bactolife and 21st Bio

Copenhagen, Denmark, 12 January 2022 – Novo Seeds, the early stage investment and company creation team of Novo Holdings, today publishes its review of 2021 – an outstanding year for venture creation and the portfolio. For more information, please see our newsletter.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH